Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

NCT01317901 is registered in ClinicalTrials.gov with Aptevo Therapeutics as lead sponsor.

NCT NCT01317901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01317901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Lead sponsor
Aptevo Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
June 30, 2013
Enrollment
12 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell small lymphocytic lymphoma recurrent